Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
LEXICON PHARMACEUTICALS, INC. (LXRX)
Sector: Healthcare; Industry: Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2022-08-05 Invus US Partners LLC 10%-Owner, Director Buy 147,390 $2.50 $368,475 No
2022-08-05 Artal International S.C.A. 10%-Owner, Director Buy 2,426,070 $2.50 $6,065,175 No
2022-08-01 Artal International S.C.A. 10%-Owner, Director Buy 16,173,800 $2.50 $40,434,500 No
2022-08-01 DEBBANE RAYMOND Director Buy 982,600 $2.50 $2,456,500 No
2021-03-15 Tessmer James F VP, Finance & Accounting Sell 22,912 $6.92 $158,440 Yes
2020-12-16 Artal International S.C.A. 10%-Owner, Director Buy 10,937,500 $3.20 $35,000,000 No
2020-12-16 Invus Public Equities, L.P. 10%-Owner, Director Buy 10,937,500 $3.20 $35,000,000 No
2019-09-18 COATS LONNEL President and CEO Buy 50,000 $3.10 $155,000 No
2019-09-18 Santini Alexander A EVP and CCO Buy 4,500 $3.36 $15,115 No
2019-09-17 COATS LONNEL President and CEO Buy 50,000 $3.13 $156,403 No
2019-09-16 DEBBANE RAYMOND Director Buy 103,042 $2.69 $277,591 No
2019-09-13 DEBBANE RAYMOND Director Buy 197,473 $2.40 $474,760 No
2019-09-16 SOBECKI CHRISTOPHER J Director Buy 25,000 $2.55 $63,718 No
2019-09-13 SOBECKI CHRISTOPHER J Director Buy 99,249 $2.41 $238,750 No
2019-08-19 COATS LONNEL President and CEO Buy 40,000 $1.35 $54,029 No
2019-08-02 Tessmer James F VP, Finance & Accounting Buy 10,000 $1.14 $11,400 No
2019-08-02 BARKER SAM L Director Buy 24,000 $1.18 $28,200 No
2018-06-28 Invus Public Equities, L.P. 10%-Owner, Director Buy 182,838 $12.51 $2,287,377 No
2018-06-25 Invus Public Equities, L.P. 10%-Owner, Director Buy 253,725 $12.99 $3,295,173 No
2018-06-21 Invus Public Equities, L.P. 10%-Owner, Director Buy 72,973 $13.29 $970,045 No
2018-06-18 Invus Public Equities, L.P. 10%-Owner, Director Buy 45,784 $12.98 $594,399 No
2018-06-12 Invus Public Equities, L.P. 10%-Owner, Director Buy 235,396 $12.80 $3,014,123 No
2018-06-08 Tessmer James F VP, Finance & Accounting Sell 10,000 $12.91 $129,076 Yes
2018-06-07 Invus Public Equities, L.P. 10%-Owner, Director Buy 325,639 $12.58 $4,095,065 No
2018-06-04 Invus Public Equities, L.P. 10%-Owner, Director Buy 416,481 $12.01 $5,002,667 No
2018-05-30 Invus Public Equities, L.P. 10%-Owner, Director Buy 433,378 $9.94 $4,306,418 No
2018-05-23 Santini Alexander A EVP and CCO Buy 745 $9.78 $7,286 No
2017-11-17 Invus Public Equities, L.P. 10%-Owner, Director Buy 180,727 $10.11 $1,826,896 No
2017-11-15 COATS LONNEL President and CEO Buy 10,000 $9.91 $99,100 No
2017-11-14 Invus Public Equities, L.P. 10%-Owner, Director Buy 575,946 $9.64 $5,554,166 No

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.